MyoKardia Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • MyoKardia's estimated annual revenue is currently $33.6M per year.(i)
  • MyoKardia received $Undisclosed in venture funding in August 2017.
  • MyoKardia's estimated revenue per employee is $745,733
  • MyoKardia's total funding is $98M.

Employee Data

  • MyoKardia has 45 Employees.(i)
  • MyoKardia grew their employee count by -10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Our Mission: Change the world for patients with cardiovascular disease through bold and innovative science. MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus: treatment of heritable cardiomyopathies, a group of genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We are a growing community of employees who enjoy working with and learning from each other. We collaborate in a way that ensures the growth of the company as well each employee individually. MyoKardia is committed to creating a culture that's centered on our core values. We seek individuals who not only offer expertise in their respective fields, but can serve as cultural leaders and role models for our values. Apply: Learn More:



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





MyoKardia News

2022-04-17 - Movers & Shakers: John Maraganore, Larry Alstiel, Brad ...

Before MyoKardia, Giankakos held leadership roles at MAP Pharmaceuticals, Codexis, Inc. and Madygen.

2022-04-17 - Evelo Biosciences names former Alnylam, MyoKardia CEOs ...

Maraganore was Alnylam's founding CEO and just left the company last year, while Gianakakos served as MyoKardia CEO for eight years until the...

2022-03-30 - ACC 2022 – Bristol's rare hit could justify Myokardia

Bristol Myers Squibb paid $13bn for mavacamten's developer, Myokardia, so it needs the project to be a hit. Today the company got a boost...

2019-09-11 - MyoKardia to Evaluate Mavacamten as an Alternative to ...

MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients.

2019-08-31 - MyoKardia Presents 36-week Data from PIONEER-OLE Study ...

Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

MyoKardia Funding

DateAmountRoundLead InvestorsReference
2017-08-09$UndisclosedUndisclosedJ.P. Morgan Securities LLCArticle